1781691-11-9 Usage
Uses
Used in Pharmaceutical Synthesis:
(4-(oxetan-3-yl)phenyl)methanol is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the formation of complex molecular structures that can possess therapeutic properties.
Used in Agrochemical Production:
In the agrochemical industry, (4-(oxetan-3-yl)phenyl)methanol is used as a building block for the development of compounds that can be applied in the agricultural sector, potentially enhancing crop protection and yield.
Used in Organic Material Synthesis:
(4-(oxetan-3-yl)phenyl)methanol is also utilized in the synthesis of organic materials, where its unique structure can be employed to create novel substances with specific properties for various applications.
Used in Chemical Research and Development:
Due to its potential pharmacological properties, (4-(oxetan-3-yl)phenyl)methanol is of interest for further research and development within the pharmaceutical field, where it may contribute to the discovery of new drugs and therapies.
Check Digit Verification of cas no
The CAS Registry Mumber 1781691-11-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,7,8,1,6,9 and 1 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1781691-11:
(9*1)+(8*7)+(7*8)+(6*1)+(5*6)+(4*9)+(3*1)+(2*1)+(1*1)=199
199 % 10 = 9
So 1781691-11-9 is a valid CAS Registry Number.
1781691-11-9Relevant academic research and scientific papers
COMPOUNDS AND METHODS OF USE
-
Page/Page column 102, (2021/03/05)
This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS
-
, (2020/12/11)
Disclosed herein are certain thiadiazolyl derivatives Formula (I): that inhibit DNA Polymerase Theta (Polθ) activity, in particular inhibit Polθ activity by inhibiting ATP dependent helicase domain activity of Polθ. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating and/or preventing diseases treatable by inhibition of Polθ such as cancer, including homologous recombination (HR) deficient cancers.
